We are monitoring the impact of COVID-19 on MEA Antifungal Drugs Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Antifungal Drugs Market Research Report – Segmented By Drug Type, Therapeutic Indications, Application & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 217
Pages: 145

MEA Antifungal Drugs Market Size (2022 to 2027)

As per the report published, the size of the Antifungal Drugs Market in the Middle East and Africa was worth USD 1.08 billion in 2022 and estimated to be growing at a CAGR of 3.462%, to reach USD 1.28 billion by 2027. The market is expected to grow enormously with the growing global population in the next few years.

Changes in environmental conditions and the spread of infectious diseases from person to person. The rising number of fungal infectious diseases such as Dermatophytosis and Aspergillosis are propelling the Middle East and Africa anti-fungal drugs market forward.  One of the other significant factors accelerating the market's growth is an aging population with weakening immune systems, where fungal infections are far more common than usual. In addition, adopting cutting-edge technologies in the production of medicines and delivering effective treatment techniques for various infectious diseases around the world will aid the market's growth.  Increased investment in research and development institutes is also projected to expand. Infections caused by fungi are considered a significant public health concern throughout the MEA.

Due to the significant frequency of fungal illnesses and the issues connected with their treatment, players are investing in R&D efforts. As a result, new antifungal drugs are being created to enhance outcomes suitable for the market.

Furthermore, during the forecast period, the Middle East and Africa Action Fund for Fungal Diseases, founded in 2019 and focused on public health advocacy for patients with fungal diseases, is predicted to drive the market.

Long-term use of these medicines has resulted in a rise in side effects, making market expansion difficult. Variations in the rate of pharmaceutical manufacturers are also slowing demand for antifungal drugs. The government's stringent standards and processes for authorizing new medications further reduce market demand. In addition, increased cancer rates, hematopoietic stem cell transplantation, and other immune-system-weakening factors are driving the market growth. The government's key restraining factors in curing these fungal infectious diseases are budget and expense regulations.

This research report on the Middle East and Africa antifungal drugs market has been segmented and sub-segmented into the following categories:

By Drug Type: 

  • Echinocandins
  • Azoles
  • Polyenes
  • Allylamines
  • Others

By Therapeutic Indications: 

  • Aspergillosis
  • Dermatophytosis
  • Candidiasis
  • Others

By Application: 

  • Powders
  • Ointments
  • Drugs
  • Pastes

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the Middle East commands a significant share in the region, and Africa is the fastest-growing region. Growing awareness of antifungal drugs is the primary driver of the market in the region.

KEY MARKET PLAYERS:

Alternaria, Pfizer, Novartis, Sanofi-Aventis, Merck & Co., Aspergillus, Kramer Laboratories, Bayer Healthcare, Enzon Pharmaceuticals, Glaxosmithkline Gilead, and Abbott Laboratories are playing a significant role in the MEA antifungal drugs market.

1. Introduction                 

                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods          

                1.4 General Study Assumptions

2. Research Methodology                           

                2.1 Introduction               

                2.2 Research Phases      

                                2.2.1 Secondary Research

                                2.2.2 Primary Research

                                2.2.3 Econometric Modelling

                                2.2.4 Expert Validation

                2.3 Analysis Design         

                2.4 Study Timeline          

3. Overview                       

                3.1 Executive Summary

                3.2 Key Inferences         

                3.3 New Developments               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                    

                4.1 Market Drivers          

                4.2 Market Restraints    

                4.3 Key Challenges         

                4.4 Current Opportunities in the Market              

5. Market Segmentation                              

                5.1 By Drug Type             

                                5.1.1 Echinocandins

                                5.1.2 Azoles

                                5.1.3 Polyenes

                                5.1.4 Allylamines

                                5.1.5 Others

                5.2 By Therapeutic Indications   

                                5.2.1 Aspergillosis

                                5.2.2 Dermatophytosis

                                5.2.3 Candidiasis

                                5.2.4 Others

                5.3 By Application           

                                5.3.1 Powders

                                5.3.2 Ointments

                                5.3.5 Drugs

                                5.3.4 Pastes

6. Geographical Analysis                              

                6.1 Introduction               

                6.2 Middle-East                

                6.3 Africa            

7. Strategic Analysis                       

                7.1 PESTLE analysis         

                                7.1.1 Political

                                7.1.2 Economic

                                7.1.3 Social

                                7.1.4 Technological

                                7.1.5 Legal

                                7.1.6 Environmental

                7.2 Porter’s Five analysis              

                                7.2.1 Bargaining Power of Suppliers

                                7.2.2 Bargaining Power of Consumers

                                7.2.3 Threat of New Entrants

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry

8. Market Leaders' Analysis                        

                8.1 Alternaria    

                                8.1.1 Overview

                                8.1.2 Product Analysis

                                8.1.3 Strategic Evaluation and Operations

                                8.1.4 Financial analysis

                                8.1.5 Legal issues

                                8.1.6 Recent Developments

                                8.1.7 SWOT analysis

                                8.1.8 Analyst View

                8.2 Pfizer            

                8.3 Novartis       

                8.4 Sanofi-Aventis          

                8.5 Merck & Co.               

                8.6 Asperqillus  

                8.7 Kramer Laboratories               

                8.8 Bayer Healthcare     

                8.9 Enzon Pharmaceuticals          

                8.10 Glaxosmithkline Gilead       

                8.11 Abbott Laboratories             

9. Competitive Landscape                           

                9.1 Market share analysis            

                9.2 Merger and Acquisition Analysis       

                9.3 Agreements, collaborations and Joint Ventures         

                9.4 New Product Launches         

10. Expert Opinions                        

                10.1 Market Outlook     

                10.2 Investment Opportunities 

Appendix                           

                a) List of Tables

                b) List of Figures              

 

  1. Middle East & Africa Antifungal Drugs Market, By Region, From 2022 - 2027 (USD Million)
  2. Middle East & Africa Antifungal Drugs Market, By Drug Type, From 2022 - 2027 (USD Million)
  3. Middle East & Africa Echinocandins Market, By Region, From 2022 - 2027 (USD Million)
  4. Middle East & Africa Azoles Market, By Region, From 2022 - 2027 (USD Million)
  5. Middle East & Africa Polyenes Market, By Region, From 2022 - 2027 (USD Million)
  6. Middle East & Africa Allylamines Market, By Region, From 2022 - 2027 (USD Million)
  7. Middle East & Africa Other Drugs Market, By Region, From 2022 - 2027 (USD Million)
  8. Middle East & Africa Antifungal Drugs Market, By Therapeutic Indications, From 2022 - 2027 (USD Million)
  9. Middle East & Africa Aspergillosis Market, By Region, From 2022 - 2027 (USD Million)
  10. Middle East & Africa Dermatophytosis Market, By Region, From 2022 - 2027 (USD Million)
  11. Middle East & Africa Candidiasis Market, By Region, From 2022 - 2027 (USD Million)
  12. Middle East & Africa Other Therapeutic Indications Market, By Region, From 2022 - 2027 (USD Million)
  13. Middle East & Africa Antifungal Drugs Market, By Application, From 2022 - 2027 (USD Million)
  14. Middle East & Africa Powders Market, By Region, From 2022 - 2027 (USD Million)
  15. Middle East & Africa Ointments Market, By Region, From 2022 - 2027 (USD Million)
  16. Middle East & Africa Drugs Market, By Region, From 2022 - 2027 (USD Million)
  17. Middle East & Africa Pastes Market, By Region, From 2022 - 2027 (USD Million)
  18. Middle East Antifungal Drugs Market, By Drug Type, From 2022 - 2027 (USD Million)
  19. Middle East Antifungal Drugs Market, By Therapeutic Indications, From 2022 - 2027 (USD Million)
  20. Middle East Antifungal Drugs Market, By Application, From 2022 - 2027 (USD Million)
  21. Africa Antifungal Drugs Market, By Drug Type, From 2022 - 2027 (USD Million)
  22. Africa Antifungal Drugs Market, By Therapeutic Indications, From 2022 - 2027 (USD Million)
  23. Africa Antifungal Drugs Market, By Application, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample